Bortezomib Induced Hepatitis B Reactivation

Table 1

Cases reported in the literature on HBV reactivation secondary to bortezomib (BOR) therapy.

Case and year reported [reference]		Serology	Before BOR	After BOR	HBV reactivation time	Outcome
Goldberg et al., 2013 [6]	72-year-old white male with MM failed therapy with thalidomide and LEN, treated with BOR	HBsAg; HbsAb; HBcAb; HBVDNA	Negative; Negative; Positive; UD	Positive; Negative; NA; 1.7 × 10^8 IU/mL	4 months after BOR	Fatal fulminant hepatic failure
Tanaka et al., 2012 [7]	72-year-old Japanese male with MM resistant to melphalan, prednisolone, and thalidomide, treated with BOR	HBsAg; HbsAb; HBcAb; HBVDNA	Negative; Positive; Negative; UD	NR; NR; NA; 2.7 × 10^5 copies/mL	10 cycles after BOR	HBV resolved after 4 weeks of entecavir with BOR resumed thereafter
Beysal et al., 2009 [8]	58-year-old male with light chain MM treated with combination chemo followed by BOR	HBsAg; HbeAg; HBcAb; HBVDNA	Positive; Positive; NA; Initially 350,000 copies/mL which became UD with lamivudine	NR; NR; NA; 20,000 copies/mL	18 months after BOR	Unclear postreactivation course

BOR: bortezomib, HBsAg: hepatitis B surface antigen, HbsAb: hepatitis B surface antibody, HBcAb: hepatitis B core antibody, HbeAg: hepatitis B e antigen, HBVDNA: hepatitis B virus deoxyribonucleic acid, NA: not applicable, and UD: undetectable.